Does Rallies show Form 4 insider transactions for NERV?

Yes. Rallies tracks NERV insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is NERV research on Rallies investment advice?

No. Rallies provides research, data, and educational context for NERV. It does not provide personalized investment advice.

NERV (Minerva Neurosciences, Inc) Stock Analysis - Insider Trades

Minerva Neurosciences, Inc (NERV) is a publicly traded Healthcare sector company. As of May 21, 2026, NERV trades at $4.67 with a market cap of $220.83M and a P/E ratio of -0.14. NERV moved +15.71% today. Year to date, NERV is +21.20%; over the trailing twelve months it is +264.49%. Its 52-week range spans $1.15 to $12.46. Analyst consensus is buy with an average price target of $10.50. Rallies surfaces NERV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading NERV stock inside the company?

Recent NERV insider activity includes Luthringer Remy sold 3.64K, Luthringer Remy sold 23.75K, Race Geoff sold 22.08K, Ahlholm Frederick W sold 3.58K, and Kupfer David sold 55.63K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

NERV Key Metrics

Key financial metrics for NERV
Metric	Value
Price	$4.67
Market Cap	$220.83M
P/E Ratio	-0.14
EPS	$-34.67
Dividend Yield	0.00%
52-Week High	$12.46
52-Week Low	$1.15
Volume	40
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-293.42M
Gross Margin	0.00%

Recent NERV Insider Trades

Luthringer Remy sold 3.64K (~$13.69K) on May 2, 2023.
Luthringer Remy sold 23.75K (~$91.45K) on May 1, 2023.
Race Geoff sold 22.08K (~$85.02K) on May 1, 2023.
Ahlholm Frederick W sold 3.58K (~$16.04K) on May 1, 2023.
Kupfer David sold 55.63K (~$48.96K) on Dec 1, 2021.

Latest NERV News

Minerva Appoints Jim O’Connor as CBO Ahead of Phase 3 Rolupe-ridone Trial — Apr 2, 2026
Minerva Neurosciences Screens First Patient in 380-Patient Phase 3 Trial with Topline Data Due 2H 2027 — Mar 31, 2026
Minerva Neurosciences Finds No Safety Concerns in Roluperidone-Olanzapine Trial, Phase 3 Underway — Mar 25, 2026

NERV Analyst Consensus

2 analysts cover NERV: 0 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $10.50.

Common questions about NERV

Who is trading NERV stock inside the company?: Recent NERV insider activity includes Luthringer Remy sold 3.64K, Luthringer Remy sold 23.75K, Race Geoff sold 22.08K, Ahlholm Frederick W sold 3.58K, and Kupfer David sold 55.63K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for NERV?: Yes. Rallies tracks NERV insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is NERV research on Rallies investment advice?: No. Rallies provides research, data, and educational context for NERV. It does not provide personalized investment advice.